|
|
|
News For LMNX;BIIB;VSTM;IMUC;PFE;AMGN;JNJ;REGN From The Last 14 Days Check below for free stories on LMNX;BIIB;VSTM;IMUC;PFE;AMGN;JNJ;REGN the last two weeks. |
|
|
| June 12, 2013 | | 08:28 EDT |  | PFE | Teva to pay $1.6B to settle with Pfizer, Nycomed over generic Protonix
 Subscribe for More Information | | | 08:02 EDT | | PFE | Pfizer wins $2.15B settlement from Teva and Sun for patent infringement
Subscribe for More Information | | | 07:39 EDT | | AMGN | Amgen, Cytokinetics announce expansion of license for omecamtiv mecarbil
Subscribe for More Information | | | 07:38 EDT |  | BIIB | Biogen price target raised to $268 from $219 at Brean Capital
Subscribe for More Information | | | 06:01 EDT |  | BIIB | Biogen downgraded to Neutral from Buy at Citigroup
Subscribe for More Information | | | June 11, 2013 | | 16:21 EDT |  | LMNX | On The Fly: Closing Wrap
Stocks on Wall Street were lower after the Bank of Japan's decision to hold off on any further stimulus measures raised investor concern. The averages recovered much of their early losses in the morning, sitting just below the flat line near noon, but the selling intensified during the second half of the session, with the market trending lower into the close. ECONOMIC EVENTS: In the U.S., NFIB's small business optimism index rose to 94.4 in May from a prior 92.1 reading. Wholesale inventories rose 0.2% in April, matching expectations, and wholesale trade rose 0.5% from the prior month, versus expectations for a 0.1% slide. The Job Openings & Labor Turnover report for April showed openings fell 3% to a seasonally adjusted 3.75M, while hiring jumped nearly 5% to 4.4M. In Asia, the Bank of Japan refrained from changing its policies following recent volatility in its stock and bond markets. The dollar weakened considerably against the Yen, losing more than 2% to trade near the Y96 level. COMPANY NEWS: Sprint (S) shares jumped 17c, or 2.37%, to $7.35 after Japan's Softbank (SFTBF) increased its offer to acquire the telecom company in the face of a potential rival bid from DISH Network (DISH). MAJOR MOVERS: Among notable gainers was Questcor (QCOR), up $5.47, or 14.9%, to $42.18 after the company acquired the right to develop Synacthen from Novartis (NVS). Also higher was Catamaran (CTRX), up $5.33, or 10.95%, to $53.99 after the company struck a ten-year strategic pharmacy benefits agreement with Cigna (CI) and its stock received upgrades from at least three firms. Among noteworthy losers was lululemon (LULU), down $14.43, or 17.54%, to $67.85 after its CEO announced plans to step down and the stock was downgraded at Sterne Agee and UBS. Also lower was GenMark Diagnostics (GNMK) which lost $1.96, or 12.95%, to $13.17, after Natural Molecular Testing launched a cardiac testing panel using technology from GenMark's competitor Luminex (LMNX). INDICES: The Dow was down 116.57, or 0.76%, to 15,122.02; the Nasdaq was down 36.82, or 1.06%, to 3,436.95; and the S&P 500 was down 16.68, or 1.02%, to 1,626.13. | | | 16:00 EDT |  | PFE | Options Update; June 11, 2013
Subscribe for More Information | | | 15:15 EDT | | PFE | Pfizer June volatility at one-year high
Subscribe for More Information | | | 15:01 EDT | | LMNX | GenMark management says no change in NMTC relationship, says Canaccord
Subscribe for More Information | | | 14:04 EDT | | LMNX | Luminex mentioned cautiously at Cowen
Subscribe for More Information | | | | 14:03 EDT | | LMNX | GenMark revenue from Natural Molecular at risk, says Piper Jaffray
Piper Jaffray believes GenMark's (GNMK) revenue from Natural Molecular Testing is at risk after that important customer struck a deal with rival Luminex (LMNX). Piper thinks GenMark shares could see near-term weakness, but keeps its Overweight rating on GenMark based on its long-term pipeline. | | | 12:32 EDT | | LMNX | On The Fly: Midday Wrap
Stocks on Wall Street were lower at midday but well off their lows after the Bank of Japan held off from implementing any additional stimulus measures. The U.S. market followed Japan's benchmark stock index lower at the open, though the averages climbed back fairly steadily during the morning and stood near session highs just a bit below the flat line near noon. ECONOMIC EVENTS: In the U.S., NFIB's small business optimism index rose to 94.4 in May from a prior 92.1 reading. Wholesale inventories rose 0.2% in April, matching expectations, and wholesale trade rose 0.5% from the prior month, versus expectations for a 0.1% slide. The Job Openings & Labor Turnover report for April showed openings fell 3% to a seasonally adjusted 3.75M, while hiring jumped nearly 5% to 4.4M. In Asia, the Bank of Japan refrained from changing its policies following recent volatility in its stock and bond markets. The benchmark Nikkei fell about 1.5% as the decision disappointed investors who may have expected some action. COMPANY NEWS: Sprint (S) shares rose over 2% after Japan's Softbank (SFTBF) increased its offer to acquire the telecom company in the face of a potential rival bid from DISH Network (DISH). MAJOR MOVERS: Among the notable gainers was Catamaran (CTRX), which was upgraded by at least three Street firms and rose 11% after announcing a ten-year strategic pharmacy benefits deal with Cigna (CI). Also higher were shares of Questcor (QCOR), which jumped 19% after buying the rights to develop Synacthen from Novartis (NVS). Among the noteworthy losers was GenMark Diagnostics (GNMK), which fell 24% after Natural Molecular Testing launched a cardiac testing panel using technology from GenMark's competitor Luminex (LMNX). Also lower were shares of yoga apparel maker lululemon (LULU), which fell 17% after its CEO announced plans to step down and the stock was downgraded at Sterne Agee and UBS. INDICES: Near noon, the Dow was down 6.68, or 0.04%, to 15,231.91; the Nasdaq was down 11.21, or 0.32%, to 3,462.56; and the S&P 500 was down 4.89, or 0.30%, to 1,637.92. | | | 11:47 EDT |  | BIIB | Deutsche Bank's biotech analyst holds an analyst/industry conference call
Biotech Analyst Karnauskas discusses Biogen's (BIIB) treatment for Multiple Sclerosis, Tecfidera, as well as reviewing IMS Tecfidera data, on an Analyst/Industry conference call to be held on June 11 at 3 pm. | | | 11:44 EDT | | LMNX | GenMark down 31% after customer picks Luminex for new product
Subscribe for More Information | | | 11:10 EDT | | LMNX | GenMark down 7% after Natural Molecular launches new product
Subscribe for More Information | | | 11:05 EDT | | LMNX | Natural Molecular launch a positive for Luminex, says Leerink
Subscribe for More Information | | | 11:03 EDT | | LMNX | Luminex partners with Natural Molecular Testing on cardiac panel
Subscribe for More Information | | | 10:56 EDT |  | JNJ | AstraZeneca to bid for Israeli biotech incubator, Globes reports
Subscribe for More Information | | | 07:42 EDT | | PFE | Boston Biotech Conferences to host a conference
Subscribe for More Information | | | 07:31 EDT | | AMGN | Goldman to host a conference
Subscribe for More Information | | |
|
|
|
|
|
|
